Nrx pharmaceuticals, inc. NRXPW.US Overview
NRXPW AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
NRXPW Current Performance
-
Nrx pharmaceuticals, inc.
1.60%
Avg of Sector
0.32%
S&P500
NRXPW Key Information
NRXPW Revenue by Segments
Browsing restrictions can be lifted for a fee.
NRXPW Net Income
Browsing restrictions can be lifted for a fee.
NRXPW Cash Flow
Browsing restrictions can be lifted for a fee.
NRXPW Profit Margin
Browsing restrictions can be lifted for a fee.
NRXPW PE Ratio River
Browsing restrictions can be lifted for a fee.
NRXPW Financial Forecast
Browsing restrictions can be lifted for a fee.
NRXPW Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
NRXPW Profile
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Price of NRXPW
NRXPW FAQ
When is NRXPW's latest earnings report released?
The most recent financial report for Nrx pharmaceuticals, inc. (NRXPW) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NRXPW's short-term business performance and financial health. For the latest updates on NRXPW's earnings releases, visit this page regularly.
How much cash does NRXPW have?
At the end of the period, Nrx pharmaceuticals, inc. (NRXPW) held Total Cash and Cash Equivalents of 5.55M, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is NRXPW's EPS continuing to grow?
According to the past four quarterly reports, Nrx pharmaceuticals, inc. (NRXPW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of NRXPW?
Nrx pharmaceuticals, inc. (NRXPW)'s Free Cash Flow (FCF) for the period is -3.48M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 5.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of NRXPW?
The latest valuation data shows Nrx pharmaceuticals, inc. (NRXPW) has a Price-To-Earnings (PE) ratio of -0.64 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.